<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182518</url>
  </required_header>
  <id_info>
    <org_study_id>262.254</org_study_id>
    <nct_id>NCT02182518</nct_id>
  </id_info>
  <brief_title>Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic Rhinitis</brief_title>
  <official_title>Double-blind, Randomized, Parallel Trial to Evaluate the Clinical Efficacy and Safety of Epinastine 10 mg + Pseudoephedrine 120 mg SR, Twice a Day, Versus Epinastine 10 mg Alone, Twice a Day, in the Treatment of Outpatients With Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of this trial is to evaluate the clinical efficacy and safety of Epinastine 10 mg +
      Pseudoephedrine 120 mg slow release (SR) administered twice a day, compared to Epinastine 10
      mg alone administered twice daily.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Classification of severity of nasal blockage by Visual Analog Scale (VAS)</measure>
    <time_frame>at the end of weeks 1, 2, 3, 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory alterations</measure>
    <time_frame>day 14, 28 and 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of premature discontinuations of the study due to adverse events</measure>
    <time_frame>up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of all adverse events</measure>
    <time_frame>up to 5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily evaluation of the nasal blockage by the patient</measure>
    <time_frame>daily up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Classification of the severity of the symptoms by the investigator</measure>
    <time_frame>at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in nasal physical examination</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in rhinorrhea symptoms evaluated by investigator</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pruritus symptoms evaluated by investigator</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sneezing symptoms evaluated by investigator</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lacrimation symptoms evaluated by investigator</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in rhinorrhea symptoms evaluated by patient using VAS</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pruritus symptoms evaluated by patient using VAS</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sneezing symptoms evaluated by patient using VAS</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lacrimation symptoms evaluated by patient using VAS</measure>
    <time_frame>Baseline and at the end of weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <arm_group>
    <arm_group_label>Epinastine + Pseudoephedrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Epinastine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinastine</intervention_name>
    <arm_group_label>Epinastine + Pseudoephedrine</arm_group_label>
    <arm_group_label>Epinastine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pseudoephedrine</intervention_name>
    <arm_group_label>Epinastine + Pseudoephedrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo during run-in period</description>
    <arm_group_label>Epinastine + Pseudoephedrine</arm_group_label>
    <arm_group_label>Epinastine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female outpatients

          -  Over 12 years old

          -  Patients who have granted their written informed consent, personally or by a legal
             representative, to be part of the study and in accomplishment of the model of informed
             consent approved by the Ethic Committee of the institution

          -  Patients with an established diagnosis of allergic perennial rhinitis under the
             clinical criteria (allergic to one or more allergens)

          -  Patients with moderate or complete nasal blockage characterizes by ≥50 mm in the VAS
             for this parameter during visits 1 and 2

          -  Patients with positive (≥3 mm compared to the negative control) skin test (&quot;Prick
             Test&quot;) to one or more of the following allergens:

               -  Dermatophagoides pteronyssinus

               -  Dermatophagoides farinae

               -  Blomia tropicalis

               -  Alternaria alternata

               -  Cladosporium herbarum

               -  Aspergillus fumigatus

               -  Penicillium notatum

               -  cat's fur

               -  dog's fur

        Exclusion Criteria:

          -  Pregnant or breast feeding women, or women without contraceptive method who:

               -  are not in the postmenopausal period and/or

               -  have not been submitted to bilateral tubal ligation or hysterectomy and/or

               -  are not under one of the following contraceptive control:

                    -  oral contraceptive

                    -  IUD (intrauterine device)

                    -  diaphragm

          -  Patients unable to understand, accept or follow the protocol instructions

          -  History of serious adverse events with antihistamines

          -  Patients under treatment with calcium antagonists or other antihypertensive drugs

          -  Patients under treatment with digitalis

          -  Patients under treatment with MAO (monoamine oxidase) inhibitors

          -  Patients under treatment with sympathicomimetics

          -  Patients that have received any of the following drugs during the periods specified
             below, before visit 1:

               -  Inhaled/Topics

                    -  short acting β2 agonists (12 hours)

                    -  long acting β2 agonists (48 hours)

                    -  ipratropium bromide (12 hours)

                    -  nasal drops without vasoconstrictors (3 days)

                    -  DSCG (disodium cromoglycate) (3 days)

                    -  nedocromil (7 days)

                    -  nasal drops with vasoconstrictors (7 days)

                    -  azelastine (14 days)

                    -  levocabastine (14 days)

                    -  corticosteroids (30 days)

                    -  corticosteroids on the site of Prick test (3 months)

                    -  other investigational drug (3 months)

               -  Oral

                    -  short acting β2 agonists (18 hours)

                    -  short acting theophylline (24 hours)

                    -  phenothiazines (48 hours)

                    -  long acting theophylline (72 hours)

                    -  anticholinergics (7 days)

                    -  antihistamines (except astemizole) (7 days)

                    -  MAO (monoamine oxidase) inhibitors (14 days)

                    -  corticosteroids (30 days)

                    -  ketotifen (3 months)

                    -  imipramine (30 days)

                    -  astemizole (2 months)

                    -  other investigational drugs (3 months)

               -  Parenteral

                    -  aminophylline (24 hours)

                    -  phenothiazines (48 hours)

                    -  antihistamines (7 days)

                    -  corticosteroids (30 days)

                    -  imipramine (30 days)

                    -  other investigational drugs (3 months)

          -  Patients under desensitization therapy

          -  Patients under therapy with antibiotics

          -  Patients with non compensate endocrine disease

          -  Patients with atrophic rhinitis

          -  Patients with rhinitis due to acetylsalicylic acid

          -  Patients with acute or chronic infectious sinusitis

          -  Patients with asthma, that need treatment with beta-2 agonists more than twice per
             week

          -  Patients with glaucoma

          -  Patients with history or renal and/or hepatic failure

          -  Patients with known platelets dysfunction due to any disease or to drugs (purpura
             thrombocytopenic idiopathic, use of anticoagulants, use of antiplatelets drugs)

          -  Patients with any oncological disease

          -  Patients with nasal septal deviation causing alteration of the nasal flux, polyps,
             anatomic/structural alterations (ex., tumors, leishmaniosis, etc.)

          -  Patients with any cardiovascular disease

          -  Patients with arterial hypertension

          -  Patients requiring halogenates anesthetics

          -  Patients with diabetes mellitus

          -  Patients with hyperthyroidism

          -  Patients with prostatic hypertrophy

          -  Patients with epilepsy or any other seizure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Epinastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

